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Abstract We examined correlates of ever injecting drugs
in Mexico among residents of San Diego, California. From
2007 to 2010, injecting drug users (IDUs) in San Diego
underwent an interviewer-administered survey. Logistic
regression identiﬁed correlates of injection drug use in
Mexico. Of 302 IDUs, 38% were Hispanic, 72% male and
median age was 37; 27% ever injected in Mexico; 43%
reported distributive syringe sharing there. Factors inde-
pendently associated with ever injecting drugs in Mexico
included being younger at ﬁrst injection, injecting heroin,
distributive syringe sharing at least half of the time, and
transporting drugs over the last 6 months. One-quarter of
IDUs reported ever injecting drugs in Mexico, among
whom syringe sharing was common, suggesting possible
mixing between IDUs in the Mexico-US border region.
Prospective studies should monitor trends in cross-border
drug use in light of recent Mexican drug policy reforms
partially decriminalizing drug possession.
Keywords Methamphetamine  Injection drug use 
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Introduction
San Diego, California is the most populous US city on the
US-Mexico border. Located on an international drug traf-
ﬁcking route spanning from South America to the United
States, illicit drugs such as heroin, methamphetamine and
cocaine are readily available in San Diego and Tijuana,
Mexico, which lies adjacent to San Diego in Mexico’s
northwest corner [1]. The corridor including the two cities
is an unbroken metropolitan area. More than 50 million
land border crossings between the US and Mexico take
place at the San Ysidro border crossing per year, making it
the busiest land border crossing in the world [2].
In 2008, the proportion of the population who reported
injecting drugs in the Mexican state of Baja California,
where Tijuana is located, was 4.8%, compared to 0.2%
elsewhere across Mexico [3]. Injection drug use is
especially common in the central business district of
Tijuana, where it is estimated that there are approxi-
mately 10,000 injection drug users (IDUs) [4]. More than
200 ‘shooting galleries’ (places where people inject drugs
in groups and syringes are rented or sold) were reported
to be in operation in Tijuana in 2004 [5]. Previous
research on IDUs in Tijuana found that heroin was the
most frequently injected drug, but methamphetamine use
is also high among IDUs [6]. The prevalence of meth-
amphetamine use is highest in Baja California among
Mexico’s 32 states [7], stemming from its widespread
production and trafﬁcking through Baja California over
the last two decades [8]. A qualitative study conducted in
Tijuana in 2004 identiﬁed abundant use, cross-border use,
and trafﬁcking of methamphetamine [8]. While compa-
rable estimates of IDU numbers are lacking for the city
of San Diego, there may be as many as 25,000–28,000 in
San Diego County [9].
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mobility related to searching for work, safety, and access to
illicit drugs, which has been associated with an elevated
risk of acquiring and transmitting blood-borne infections
[10]. For example, shooting gallery use and sharing of
injection equipment was elevated among IDUs who had
recently migrated from Puerto Rico to New York City [11].
Another study found associations between various drug
scene roles, such as selling drugs and needles, and risky
injection behaviors among Puerto Rican IDUs with high
levels of mobility who travelled between the US and Puerto
Rico [12]. In Brazil, spread of malaria from an endemic
region to a non-endemic region was linked to syringe
sharing among mobile IDUs [13]. Mixing between IDUs
has also been implicated in HIV transmission across the
border from Northeastern India into Nepal [14].
In border regions, where differences in neighboring
drug markets may serve as a motivator for cross-border
mobility, the role of injection drug use in the transmission
of infectious diseases is of special interest. In a review
article, Rachlis et al. listed many examples of links
between drug trafﬁcking, drug market volatility, and the
spread of HIV along drug trafﬁcking routes in several
regions of the world, including Central Asia, port towns
along the Black Sea and northeastern states in India
adjacent to Myanmar [10]. In the border region of China
and Vietnam, Chinese HIV-positive IDUs were more
likely to live closer to the border and cross the border to
purchase drugs than HIV-negative IDUs [15, 16], which is
believed to have contributed to the spread of HIV among
IDUs in Vietnam [17].
High and/or rising prevalence of HIV, HCV, TB and
syphilis among IDUs in the border region may pose risks to
IDUs who travel to Tijuana from neighboring San Diego to
obtain and/or inject drugs and for those traveling from
Tijuana to San Diego. HIV prevalence among male and
female IDUs in Tijuana was 4 and 12%, respectively [18],
compared to 5% among male and 1% among female IDUs
in San Diego (personal communication, Dr. Richard
Garfein Sept 2010). The prevalence of latent tuberculosis
infection was 67% among IDUs in Tijuana in 2007 [19],
and cross-border mobility of IDUs in the US-Mexico bor-
der region was associated with heightened odds of lifetime
TB risk [20]. Prevalence of syphilis infection among IDUs
in Tijuana in 2006–2007 was 6% among male and 16%
among female IDUs [21]. The high proportion of active
syphilis infections among IDUs in Tijuana suggests that
syringe sharing could promote parenteral syphilis trans-
mission [22].
Spread of infections in the Mexico-US border region
may be facilitated by highly mobile populations, including
IDUs, who reside close to the border and can cross freely
between these neighboring countries, but few studies have
examined this phenomenon empirically. A study by
members of our team in 2005 showed that among 222
IDUs in Tijuana, 12% crossed the border to the US in the
6 months prior to the interview; IDUs who had been
deported to Mexico injected more frequently and were less
likely to receive medical care, drug treatment, or HIV
testing [23], which could imply a greater risk for blood
borne transmission. In a larger study of 1056 IDUs who
resided in Tijuana in 2006–2007, 78% had ever crossed
into the United States and 58% had used drugs there [24].
In August 2010, federal Mexican drug policy was
enacted that partially decriminalized possession of small
quantities of speciﬁc drugs for personal consumption (e.g.,
methamphetamine, heroin, cocaine, marijuana, LSD) [25].
As these laws become adopted in Mexican states, this
policy shift could affect drug using behaviors and mobility
in the Mexico-US border region. To our knowledge, no
studies have examined the frequency and factors associated
with border crossing among IDUs in the US who travel to
Mexico. The current study, which was conducted prior to
changes in Mexico’s drug possession laws, examined the
prevalence and correlates of ever injecting drugs in Mexico
among IDUs living in San Diego.
Methods
Data Collection
Between 11/2007 and 02/2010, we recruited IDUs in San
Diego, California to study their experiences with retail
illicit drug markets and cross-border mobility. Eligibility
criteria included residing in San Diego County, having
injected drugs within the last 6 months and being at least
18 years old. Participants were recruited through street
outreach at the San Diego syringe exchange program,
through word of mouth, and referrals from other observa-
tional studies.
The study instrument consisted of a questionnaire elic-
iting data on demographic characteristics, drug use
behaviors such as injection frequency, receptive syringe
sharing (i.e., having used a needle someone else had
already used), distributive syringe sharing (i.e. having
passed on, rented or sold a used needle they had used to
someone else), and participation in the drug market over
the last 6 months (e.g. selling, packaging or transporting
drugs). Participants were speciﬁcally asked if they traveled
to Mexico in their lifetime and in the last 6 months, if they
injected drugs in Mexico and if they engaged in receptive
and distributive syringe sharing in Mexico, but were not
speciﬁcally asked if they transported drugs over the border.
Additionally, information was obtained on perceived
changes in drug market conditions, such as whether the
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cocaine and other drugs had increased, decreased or stayed
the same over the last 6 months. Variables reﬂecting per-
ceptions and participation in the drug market were based in
part on questions derived from a survey conducted by the
San Diego Association of Governments among San Diego
arrestees. Questions were interviewer-administered via
computer-assisted programmed interview (CAPI) using
Questionnaire Development System (QDS) software
(Nova, Bethesda, Maryland, USA). Subjects were com-
pensated USD $20 for participation. The UCSD Human
Research Protection Program approved the study protocol.
Laboratory Testing
HIV antibody testing was conducted using the OraQuick
ADVANCE Rapid HIV-1/2 Antibody Test (OraSure
Technologies, Inc., Bethlehem, PA). Pre and post test HIV
counseling was conducted for all participants. Those who
were previously unaware of their HIV status and tested
HIV-positive were referred to county clinics for conﬁr-
matory testing, counseling and medical care. Participants
were asked whether they had ever tested positive for
syphilis, gonorrhea, and Chlamydia, chancroid, and other
sexually transmitted infections (STIs) but were not tested
for these infections.
Statistical Analysis
Participants who had ever injected drugs in Mexico were
compared to those who had not, ﬁrst using descriptive
statistics (chi-square tests for categorical variables, Fisher’s
exact test for dichotomous variables, and Wilcoxon rank-
sum tests for continuous variables). Logistic regression was
used to identify correlates of ever having injected drugs in
Mexico, selecting variables that were signiﬁcant at the 5%
level in univariate models for potential inclusion in mul-
tivariate models. The likelihood ratio test was used to
compare nested multivariate models. Variables that were
signiﬁcant at P B 0.05 were retained for the ﬁnal model. In
order to substantiate our results we repeated our logistic
regression analysis on a subset of subjects, comparing
those who injected in Mexico during the last 6 months to
those who had not.
Results
Of the 304 participants initially enrolled, two were
excluded because they had missing information on whe-
ther or not they had ever injected drugs in Mexico. Of the
302 IDUs included in the analysis, most were male
(71.5%) and born in the United States (91.7%). Although
68.1% were White, 38 (12.6%) described themselves as
Latino/Hispanic and 77 (25.5%) as ‘‘other’’; 7 (2.3%) were
born in Mexico while 14 (4.6%) were born in another
country. Median age was 37 and median age at ﬁrst
injection of drugs was 21 years (range: 9–53), respec-
tively. Overall, 242 (80.1%) ever crossed the border into
Mexico and 97 (32.2%) crossed into Mexico in the last
6 months. A total of 83 (27.5%) reported ever injecting
drugs in Mexico, of whom 36 (43.4%) reported having
done so in the last 6 months. Of the 83 subjects who ever
injected in Mexico, 73.5% had injected with someone else,
41.0% engaged in distributive syringe sharing and 21.7%
engaged in receptive syringe sharing while they were in
Mexico.
As shown in Table 1, compared to other IDUs, those
who had ever injected in Mexico were younger at ﬁrst
injection (median age 19 vs. 21 years; P = 0.002), and
were more likely to report the following behaviors during
the last 6 months: injecting heroin, injecting drugs more
than once per week, renting or lending a syringe at least
half the time, and injecting with someone in the US.
Those who had ever injected in Mexico were also more
likely to report being involved in the drug market, for
example, by packaging drugs or transporting drugs in the
last 6 months. Finally, IDUs who had ever injected in
Mexico were more likely to report the perception that the
price of at least one drug went down or stayed the same
in the last 6 months, with the majority of those
responding noticing that the price of methamphetamine
went down or stayed the same (P\0.05). It should be
noted that these risk behaviors could have occurred in
Mexico or the US or both. Variables that did not differ
between those who injected in Mexico and those who did
not included HIV serostatus, self reported STI status, and
sexual behaviors.
Factors that were independently associated with ever
injecting drugs in Mexico in multivariable analysis inclu-
ded being younger at ﬁrst injection (AOR = 0.95 per year;
95% CI = 0.91–0.99), injecting heroin (AOR = 2.11; 95%
CI = 1.15–3.88), renting or lending a used syringe to
another person at least half of the time (AOR = 2.35; 95%
CI = 1.11–4.95), and transporting drugs over the last
6 months (AOR = 2.24; 95% CI = 1.22–4.11) (Table 2).
Perceiving that the price of at least one drug went down or
stayed the same over the last 6 months was also indepen-
dently associated with ever injecting drugs in Mexico
(AOR = 2.60; 95% CI = 1.30–5.18). A multivariate
model that replaced the variable ‘transporting drugs’ with
‘packaging drugs’ yielded similar associations (results not
shown). The sub-analysis that compared IDUs who injec-
ted in Mexico during the last 6 months versus those who
had not generated similar parameter estimates (results not
shown).
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In this sample of IDUs recruited in San Diego, CA from
2009 to 2010, approximately one-quarter reported ever
injecting drugs in Mexico, of whom nearly half reported
injecting drugs in Mexico over the last 6 months. More
than one-ﬁfth reported receptive syringe sharing in Mexico
and two-ﬁfths reported distributive syringe sharing in
Mexico, suggesting there is considerable cross-border
mobility and possible mixing among IDUs in San Diego
who travel to Tijuana. IDUs who ever injected drugs in
Mexico were more likely to be younger heroin injectors
who were involved in some riskier drug behaviors, such as
syringe sharing, than those who never injected in Mexico.
They were also more likely to be involved in the drug
market and to report perceived changes in San Diego’s
retail drug prices.
In the current study, IDUs who had ever injected in
Mexico were signiﬁcantly more likely to have engaged in
distributive syringe sharing and transporting drugs. The
ﬁnding that IDUs who ever injected drugs in Mexico were
more likely to have transported or packaged drugs implies
a connection to the illicit drug trade. Various roles in the
drug scene, such as selling drugs, have been associated
with elevated odds of injection drug use and syringe
sharing [12, 26]. Another study from Asia found similar
results along a major drug supply route: IDUs who traveled
from China, where drugs were scarce, to a region in
Table 1 Demographic, injection, and drug perception risks associated with cross-border injection drug use by San Diego drug users traveling to
Tijuana, Mexico (N = 302)
Unadjusted proportions
Injected in Mexico
(N = 83)
Did not inject in Mexico
(N = 219)
Univariate OR (95% CI) P value
Demographics
Female versus male 22 (26.5%) 57 (26.0%) 1.00 (0.56–1.78) 0.99
White versus Hispanic/other 60 (72.3%) 127 (58.0%) 1.52 (0.68–3.42) 0.31
Born in the United States 76 (91.6%) 205 (93.6%) 0.49 (0.11–2.26) 0.66
At least high school education 59 (71.1%) 142 (64.8%) 1.33 (0.77–2.31) 0.31
Injection Risks/Behaviors
Median age ﬁrst injected drugs (IQR) 19 (15,23) 21 (18,29) 0.93 (0.89–0.97) <0.01
Injected heroin* 55 (66.3%) 92 (42.0%) 2.71 (1.60–4.60) <0.01
Injected heroin[once per week * 40 (48.2%) 62 (28.3%) 2.36 (1.40–3.97) <0.01
Injected methamphetamine* 57 (69.5%) 145 (66.2%) 1.16 (0.67–2.01) 0.59
Injected drugs[once per week* 63 (75.9%) 130 (62.8%) 1.87 (1.05–3.32) 0.03
Rented or lent syringe at least half the time* 20 (24.1%) 25 (11.7%) 2.39 (1.24–4.59) <0.01
Injected with someone in US* 33 (39.8%) 19 (8.8%) 6.81 (3.57–12.97) <0.01
Crossed the US-Mexico border* 40 (48.8%) 57 (26.0%) 2.71 (1.60–4.59) <0.01
Drug Market Roles
Packaged drugs* 25 (32.1%) 34 (16.6%) 2.37 (1.30–4.33) <0.01
Transported drugs* 32 (41.0%) 53 (25.9%) 2.00 (1.15–3.45) 0.01
Drug Perceptions
Price of at least one drug went down
or stayed the same*
62 (76.5%) 124 (60.2%) 2.17 (1.20–3.85) <0.01
Purity of at least one drug went up* 12 (15.0%) 19.0 (9.6%) 1.49 (0.87–2.56) 0.15
Price of meth went down or stayed the same* 66 (81.5%) 137 (66.5%) 2.22 (1.18–4.17) 0.01
Bold values indicate signiﬁcant at the P\0.05 level
* Past 6 months
Table 2 Factors independently associated with cross-border injec-
tion drug use by San Diego drug users traveling to Tijuana, Mexico
(n = 302)
AOR (95% CI)
Age at ﬁrst drug injection (per year increase) 0.95 (0.91–0.99)
Injected heroin* 2.11 (1.15–3.88)
Rented or lent syringe at least half of the time* 2.35 (1.11–4.95)
Involved in transporting drugs* 2.24 (1.22–4.11)
Perceived that the price of at least one drug
decreased or stayed the same*
2.60 (1.30–5.18)
* Past 6 months
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123Vietnam where drugs were plentiful, were more likely to
cross the border to purchase drugs than non-IDUs [27].
IDUs who had ever injected drugs in Mexico were two
and a half times more likely to have perceived a decrease in
the price of at least one drug in San Diego compared to
IDUs who had never injected in Mexico. This association
appeared to be driven by a perceived decrease in the retail
price of methamphetamine. Since the mid-1990s, Mexican
methamphetamine trafﬁckers have been operating ‘‘super
labs’’ which are capable of producing more than 10 pounds
of methamphetamine in 24 h [28]. These super labs have
been implicated in the increased supply of methamphet-
amine from Mexico to the United States, and may have
affected its retail price. Regulation of precursor chemicals
by the United States and Canada in the early 2000s limited
supply of methamphetamine produced by super labs [29]
and may have led to increased prices. A 2008 report from
San Diego found that 76% of local methamphetamine ar-
restees perceived an increase in the price of methamphet-
amine between 2006 and 2008 [30], but a more recent
report from 2009 found mixed results for market price
trends depending on the quantity, with decreasing prices
per-pound, indicating a possible shift in the market [31].
The ﬁnding that San Diego IDUs who injected in Mexico
had perceived a price decrease in drugs is unexpected,
given the San Diego methamphetamine market conditions
at the time of the study. Our ﬁndings could imply that IDUs
who injected in Mexico and who were price-sensitive could
be crossing into Mexico to purchase methamphetamine,
where it is less expensive, with the intention of reselling it
in San Diego. This is speculative, however, and further
investigation is needed to explain this ﬁnding. IDUs who
are involved in the drug trade may be more sensitive to
changes in the drug market and could ostensibly be more
affected by recent changes to Mexico’s drug possession
laws if methamphetamine becomes easier to acquire in
Mexico. However, since our analysis was cross-sectional
and the relationships between mobility and drug market
factors such as purity, price and availability are complex,
caution should be exercised in the interpretation of our
data. For example, price and purity of methamphetamine in
the United States are also subject to inﬂuences such as
policy changes in the US and Mexican regulating precursor
chemicals [32].
In support of the literature indicating that IDUs who are
mobile tend to be more likely to report riskier injection
behavior sharing [10], IDUs who injected drugs in Mexico
were more likely to have engaged in distributive syringe
sharing, and were younger when they initiated injection
drug use. A recent study of IDUs living in Tijuana showed
that 78% had ever crossed the border into the United States,
but only 7% had done so in the last year [24]. In contrast,
our study found that 80% of IDUs living in San Diego had
ever crossed the Mexican border, of whom 32% had done so
in the last 6 months. Almost half of Tijuana IDUs had
injected with someone from the United States, though it is
unknown whether those injection events occurred in the US
or in Mexico [24]. These data suggest that there is consid-
erable mobility among IDUs living in the US/Mexico bor-
der region, and raises important questions about the extent
of interaction among US- and Mexico-based IDUs. Future
studies will be needed to explore the extent to which IDUs
engage in drug and sexual risk behaviors with members of
social networks on either side of the border, which could
have important implications for the transmission of blood-
borne pathogens.
Our analysis was limited by the fact that our outcome
variable captured lifetime injection experiences in Mexico
relative to several of the independent variables whose time
frame was during the 6 months before the interview.
However, nearly half of our participants who ever injected
in Mexico crossed into Mexico during the last 6 months, of
whom about one-quarter of those injected in Mexico.
Additionally, our sub-analysis that compared those who
injected in Mexico during the last 6 months versus those
who had not yielded similar associations, suggesting that
this issue may not have seriously biased our ﬁndings. Other
limitations include the potential for selection bias due to
convenience sampling, as well as socially desirable
responding which may have attenuated some associations.
Prospective studies are needed to monitor trends in
cross-border drug use, its relationship to the drug market,
and its impact on behaviors and health outcomes for resi-
dents of both the US and Mexico. Mexico’s drug policy
reforms which partially decriminalize small amounts of
illicit drugs could potentially inﬂuence infectious disease
transmission by enticing IDUs from the US to cross the
Mexican border more frequently as ‘drug tourists’. Such
trends should be monitored closely.
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